Brief Overview

Abstract

This article reviews the burden of rotavirus (RV) disease and the role, types, and coverage of RV vaccines (RVVs) in India as well as globally. Establishing the epidemiology and burden of RV disease became an early priority. In the world, diarrheal infections are the second greatest cause of death in children, accounting for one in nine fatalities. Before the widespread use of RV vaccinations, an estimated 453,000 children under the age of 5 died worldwide from RV gastroenteritis (RVGE) in 2008. That's why the World Health Organization (WHO) recommends that RV vaccination should be included in national immunization programs to prevent RVGE. Several vaccines have been invented, and they are an efficient way to shield kids from RVGE. Four RVVs are currently approved by the WHO and accessible worldwide: the monovalent live attenuated human RVV (Rotarix); the pentavalent human-bovine reassortant RVV (RotaTeq); the naturally occurring monovalent neonatal bovine-human reassortant neonatal G9P[11], also known as 116E (Rotavac) and the Pentavalent, human-bovine RVV Rotasiil; all of them WHO prequalified, well tolerated with variable efficacy and protective value distributed globally. To control the RV disease among children, it is crucial to support the development of the next generation of vaccines. If the new vaccine is found to be secure, more efficient, simple to administer, and inexpensive for all, the disease may be controlled more efficiently in the near future.